On Mar 21, 2019 46.85 % to Target, SAGE Therapeutics (NASDAQ:SAGE) Stock Buy Rating Maintained by Stifel Nicolaus.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Corporate Logo

Big Money Sentiment decreased to 1.07 in Q4 2018. It has change of 0.08, from 2018Q3’s 1.15. The ratio fall due to Sage Therapeutics, Inc. positioning: 44 sold and 60 reduced. 35 funds took stakes and 76 increased stakes. Investors holded 46.64 million in 2018Q3 but now own 47.40 million shares or 1.62% more.

Bluecrest Limited accumulated 0.01% or 2,665 shs. Nicholas Prtn Limited Partnership has invested 0.55% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Raymond James And Associate holds 0% of its capital in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 22,505 shs. Jane Street Group Incorporated Limited Liability Corporation invested in 5,106 shs. Employees Retirement Of Ohio owns 27,460 shs or 0.02% of their US capital. Artisan Ptnrs Ltd Partnership has invested 0.05% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Marshall Wace Llp stated it has 0.07% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Moreover, Legal & General Group Public Limited has 0% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Great West Life Assurance Communications Can has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Eagle Asset Incorporated holds 0.39% or 647,342 shs. 1.06 million are held by State Street. Mirae Asset Global Invs Limited holds 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE) or 8,676 shs. Tiverton Asset Mgmt Limited Company reported 0.04% stake. Public Employees Retirement Association Of Colorado stated it has 6,947 shs. Virginia Retirement System Et Al reported 2,700 shs.

Sage Therapeutics, Inc. registered $4.45 million net activity with 0 insider buys and 2 insider sales since January 23, 2019. On Wednesday, January 23 $1.01M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by FRATES JAMES M.

Reiterated SAGE Therapeutics (NASDAQ:SAGE) Rating.

Stifel Nicolaus’s Equity research analysts have $232 target price which indicates upside potential of 46.85 % on SAGE Therapeutics (NASDAQ:SAGE). an analyst note of the firm was released on Wednesday, 20 March.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Total analysts of 10 have positions in Sage Therapeutics (NASDAQ:SAGE) as follows: 9 rated it a “Buy”, 1 with “Sell” and 0 with “Hold”. The positive are 90%. Since October 11, 2018 according to StockzIntelligence Inc Sage Therapeutics has 15 analyst reports. In Tuesday, February 19 report Oppenheimer maintained the stock with “Buy” rating. On Monday, November 5 the firm has “Outperform” rating given by RBC Capital Markets. On Wednesday, December 19 the stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Overweight” rating given by Morgan Stanley. On Wednesday, March 20 the firm has “Buy” rating by SunTrust given. On Wednesday, March 20 the stock has “Buy” rating by Stifel Nicolaus. In Wednesday, February 20 report RBC Capital Markets maintained it with “Buy” rating and $249 target. On Tuesday, February 19 the rating was maintained by Cowen & Co with “Buy”. On Monday, February 25 Morgan Stanley maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) with “Buy” rating. In Tuesday, February 19 report Piper Jaffray maintained the stock with “Buy” rating. In Thursday, October 11 report Morgan Stanley maintained it with “Overweight” rating and $230 target.

Ticker’s shares touched $157.98 during the last trading session after 3.62% change.Sage Therapeutics, Inc. is downtrending after having declined 3.58% since March 21, 2018. SAGE has 750,322 volume or 14.10% up from normal. The stock underperformed the S&P 500 by 7.95%.

Sage Therapeutics, Inc. (NASDAQ:SAGE)’s earnings release is expected by WallStreet on May, 2, according to Zacks. This year’s EPS analyst estimate is expected to be $-3.14. That is 86.90 % down compareed to $-1.68 EPS for last year. -7.10 % EPS growth is what analysts predict. $-3.38 EPS was reported for previous quarter.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders.The firm is valued at $8.05 billion. The Company’s lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression .Currently it has negative earnings. The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which has completed Phase II clinical trials for the treatment of PPD, major depressive disorders, bipolar depression, Parkinson's disease, and sleep disorders; and SAGE-718, an oxysterol positive allosteric modulator of NMDA receptors for the treatment of depression, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, Huntington's disease, and neuropathic pain.

For more Sage Therapeutics, Inc. (NASDAQ:SAGE) news published briefly go to: Nasdaq.com, Benzinga.com, Globenewswire.com, Benzinga.com or Nasdaq.com. The titles are as follows: “Boston Calling Shares New Details About the Festival’s Arena Stage – Nasdaq” published on March 21, 2019, “30 Stocks Moving In Wednesday’s Pre-Market Session – Benzinga” on March 20, 2019, “Market Trends Toward New Normal in Macy’s, Comerica, JetBlue Airways, Intersect ENT, Stanley Black & Decker, and Sage Therapeutics — Emerging Consolidated Expectations, Analyst Ratings – GlobeNewswire” with a publish date: March 05, 2019, “Etsy Inc. (NASDAQ:ETSY), Dillard’s, Inc. (NYSE:DDS) – 5 Stocks Moving In Monday’s After-Hours Session – Benzinga” and the last “Determine, Inc. Explores the Many Advantages of a Fully-Integrated Source-to-pay Cloud Platform in Live Webinar, March 26 – Nasdaq” with publication date: March 20, 2019.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.